Neurontin Antitrust Litigation

Berger Montague served as class counsel in this antitrust class action, winning a $190 million settlement on behalf of a class of direct purchasers of the brand-name prescription drug Neurontin. The plaintiffs alleged that Pfizer, Inc., one of the nation’s largest pharmaceutical manufacturers, and its subsidiary Warner-Lambert Co., illegally maintained a monopoly in the market for Neurontin, a popular anti-epilepsy drug, by filing sham patent litigation against generic competitors in order to delay the marketing of less expensive generic substitutes for Neurontin. The plaintiffs alleged that as a result of Pfizer’s violation of the antitrust laws, purchasers paid hundreds of millions of dollars too much for this anti-epilepsy drug. The Berger Montague team on the case was led by Shareholder Eric L. Cramer.

If you or your company has been harmed by anticompetitive conduct or any conduct that you believe violates the antitrust laws, please contact Berger Montague.

About Berger Montague

Berger Montague is a national law firm focusing on complex civil litigation in federal and state courts throughout the United States. For over half a century, Berger Montague has played lead roles in consequential, precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago, Minneapolis, San Diego, San Francisco, Toronto, and Washington, D.C.